Movement Disorders Program
The Movement Disorders Program evaluates, diagnoses, and treats all movement disorders including:- Tremors
- Parkinson’s disease
- Dystonia
- Restless leg syndrome
- Huntington’s disease or chorea
Dr. Way is the principal investigator of the PROSEEK study at Renown. PROSEEK is a drug trial that is studying a c-Abl inhibitor developed by SUN pharmaceuticals that has shown promise in slowing the progression of Parkinson’s disease. To be a candidate for the study, one must fulfill at least the following criteria:
- Age > 50 years
- Diagnosed with Parkinson’s disease within the last 3 years
- Not on medication for treatment of Parkinson’s disease aside from monoamine oxidase B (MAOB) inhibitors.
ncG1vNJzZmivp6x7s7HNqK6nZp%2BntHCUxJqjraBdiLKzwsicnKxnfprCs7vSnKCeppOawHCaxK6pqKSfnMZwmc6vnKadnql6hbXSqKmdnaKoepG%2BzqCpmqU%3D